Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica
Mesothelioma (peritoneal, pericardial, or tunica vaginalis testis)
Initial criteria
- age ≥ 18 years
- used as subsequent therapy
- used in combination with bevacizumab
- has malignant peritoneal, pericardial, or tunica vaginalis testis mesothelioma
- prescribed by or in consultation with an oncologist
Approval duration
1 year